Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Albiglutide

CER-4-T2D

GSK · Phase n/r · Active, not recruiting · Enrollment 781430

NCT05220917

ArmPopulationDoseWeeksEstimandWeight change
SGLT-2i (Comparison 1)T2D onlyn/rn/rn/rn/r
DPP-4i (Comparison 1)T2D onlyn/rn/rn/rn/r
SGLT-2i (Comparison 2)T2D onlyn/rn/rn/rn/r
GLP-1 RA (Comparison 2)T2D onlyn/rn/rn/rn/r
GLP-1 RA (Comparison 3)T2D onlyn/rn/rn/rn/r
DPP-4i (Comparison 3)T2D onlyn/rn/rn/rn/r
SGLT-2i (Comparison 4)T2D onlyn/rn/rn/rn/r
SU (Comparison 4)T2D onlyn/rn/rn/rn/r
GLP-1 RA (Comparison 5)T2D onlyn/rn/rn/rn/r
SU (Comparison 5)T2D onlyn/rn/rn/rn/r
DPP-4i (Comparison 6)T2D onlyn/rn/rn/rn/r
SU (Comparison 6)T2D onlyn/rn/rn/rn/r
SGLT2i (Comparison 7)T2D onlyn/rn/rn/rn/r
GLP-1 RA (Comparison 7)T2D onlyn/rn/rn/rn/r
DPP-4i (Comparison 7)T2D onlyn/rn/rn/rn/r
SU (Comparison 7)T2D onlyn/rn/rn/rn/r
SGLT2i (Comparison 8)T2D onlyn/rn/rn/rn/r
GLP-1 RA (Comparison 8)T2D onlyn/rn/rn/rn/r
DPP-4i (Comparison 8)T2D onlyn/rn/rn/rn/r